Abstract:Objective To describe the clinical features and effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A(H1N1) virus infection.Design Opportunistic retrospective review of medical charts of patients with confirmed 2009 H1N1 identified through the national surveillance system in China from May to July 2009.Setting Under coordination of the Ministry of Health, local health departments were asked to collect medical records of confirmed patients and send them to the Chinese Centre for Disease Control and Prevention on a voluntary basis as part of the public health response.Population 1291 patients with confirmed 2009 H1N1 infection and available data for chart review.Main outcome measures Demographic characteristics, comorbidities, symptoms and signs, laboratory tests, findings on chest radiography, antiviral treatment, duration of fever, and duration of viral RNA shedding.Results The median age of 1291 patients was 20 years (interquartile range 12-26); 701 (54%) were male. The most common symptoms were fever (820, 64%), cough (864, 67%), sore throat (425, 33%), sputum (239, 19%), and rhinorrhoea (228, 18%). Of 920 patients who underwent chest radiography, 110 (12%) had abnormal findings consistent with pneumonia. Some 983 (76%) patients were treated with oseltamivir from a median of the third day of symptoms (2-4). No patients required admission to the intensive care unit or mechanical ventilation. 2009 H1N1 was shed from one day before onset of symptoms to up to eight days after onset in most (91%) patients, with a median of 5 (3-6) days of shedding after onset. Treatment with oseltamivir significantly protected against subsequent development of radiographically confirmed pneumonia (odds ratio 0.12, 95% confidence interval 0.08 to 0.18), and treatment started within two days of symptom onset reduced the duration of fever and viral RNA shedding.Conclusions Chinese patients with 2009 H1N1 infection predominantly presented with features of uncomplicated, self limiting acute respiratory illness. 2009 H1N1 might be shed longer than seasonal influenza virus. Treatment with oseltamivir was associated with a significantly reduced development of radiographically confirmed pneumonia and a shorter duration of fever and viral RNA shedding. Though these patients benefited from treatment, the findings should be interpreted with caution as the study was retrospective and not all patients underwent chest radiography.

Efficacy of oseltamivir-peramivir combination therapy compared to oseltamivir monotherapy for Influenza A (H7N9) infection: a retrospective study

Influenza A-associated Severe Pneumonia in Hospitalized Patients: Risk Factors and NAI Treatments.

Antiviral Therapy And Outcomes Of Patients With Pneumonia Caused By Influenza A Pandemic (H1n1) Virus

The Neuraminidase Inhibitor Oseltamivir Is Effective Against A/Anhui/1/2013 (H7n9) Influenza Virus In A Mouse Model Of Acute Respiratory Distress Syndrome

Effectiveness of Oseltamivir on Disease Progression and Viral RNA Shedding in Patients with Mild Pandemic 2009 Influenza A H1N1: Opportunistic Retrospective Study of Medical Charts in China

Clinical Effectiveness of Intravenous Peramivir Compared With Oseltamivir in Patients With Severe Influenza A With Primary Viral Pneumonia: A Randomized Controlled Study

Clinical Efficacy Observation of Atomization Inhalation Combined with Oral Administration of Oseltamivir in 4 Cases with H7N9 Avian Influenza

Poor Responses to Oseltamivir Treatment in a Patient with Influenza A (H7N9) Virus Infection.

Oseltamivir Compared with the Chinese Traditional Therapy Maxingshigan–Yinqiaosan in the Treatment of H1N1 Influenza

Effect of Oseltamivir on the Hemagglutination Test and Hemagglutination Inhibition Test of the Influenza A(H3N2) Virus in China.

Oseltamivir Treatment for Influenza During the Flu Season of 2018–2019: A Longitudinal Study

A Multicentre, Randomized, Controlled Trial of Oseltamivir in the Treatment of Influenza in a High-Risk Chinese Population

Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients with Avian Influenza A(H7N9) Virus

Combinations of Oseltamivir and Fibrates Prolong the Mean Survival Time of Mice Infected with the Lethal H7N9 Influenza Virus

A Multicenter Randomized Controlled Study of the Efficacy and Safety of Oseltamivir in the Treatment of Influenza in a High Risk Population

A Meta-Analysis Comparing the Efficacy and Safety of Peramivir with Other Neuraminidase Inhibitors for Influenza Treatment

Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief

Clinical effectiveness of neuraminidase inhibitors—oseltamivir, zanamivir, laninamivir, and peramivir—for treatment of influenza A(H3N2) and A(H1N1)pdm09 infection: an observational study in the 2010–2011 influenza season in Japan

Effectiveness of Neuraminidase Inhibitors to Prevent Mortality in Patients with Laboratory-Confirmed Avian Influenza A H7N9.

Comparative Effectiveness of Oseltamivir Versus Peramivir for Hospitalized Children (aged 0-5 Years) with Influenza Infection.

A randomized controlled study of peramivir, oseltamivir and placebo in patients with mild influenza